Protection of nigral neurons by GDNF-engineered marrow cell transplantation

Area of Science:

• Neuroscience
• Stem Cell Biology
• Gene Therapy

Background:

• Marrow stromal cells possess stem cell-like properties and can migrate to non-hematopoietic tissues, including the brain.
• Parkinson's disease is characterized by the loss of dopaminergic neurons, leading to motor deficits.
• Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a potent neurotrophic factor for dopaminergic neurons.

Purpose of the Study:

• To investigate the potential of marrow-derived cells as vehicles for delivering Glial Cell Line-Derived Neurotrophic Factor (GDNF) to the brain.
• To evaluate the therapeutic efficacy of GDNF-transduced marrow cells in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-induced mouse model of Parkinson's disease.

Main Methods:

• Cross-sex intravenous bone marrow transplantation (BMT) was performed using male donor cells transduced with GDNF (GDNF-BMT) or non-manipulated marrow (Control-BMT) into female recipient mice.
• Mice were subjected to systemic 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) injections to induce Parkinsonism.
• Neuroprotection and functional recovery were assessed by quantifying tyrosine hydroxylase-immunoreactive neurons, striatal terminal density, and motor activity.

Main Results:

• GDNF-BMT mice exhibited significantly more tyrosine hydroxylase-immunoreactive nigral neurons and greater striatal terminal density compared to Control-BMT mice eight weeks post-MPTP exposure.
• A significant difference in motor activity was observed between the GDNF-BMT and Control-BMT groups following initial hyperactivity.
• GDNF-expressing donor marrow-derived cells were detected in the brains of GDNF-BMT mice, confirming successful engraftment and gene expression.

Conclusions:

• Marrow-derived cells that engraft in the brain can express biologically active gene products.
• These cells serve as effective vehicles for therapeutic gene transfer to the central nervous system.
• Marrow cell-based delivery of GDNF shows promise for neuroprotection in Parkinson's disease models.